share_log

Monte Rosa Therapeutics Analyst Ratings

Monte Rosa Therapeutics Analyst Ratings

蒙特羅薩治療分析師評級
Benzinga Analyst Ratings ·  2023/01/03 04:37
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/03/2023 149.67% Wells Fargo → $19 Upgrades Equal-Weight → Overweight
10/13/2022 189.09% UBS → $22 Initiates Coverage On → Buy
08/15/2022 162.81% Jefferies → $20 Initiates Coverage On → Buy
05/12/2022 175.95% Piper Sandler $40 → $21 Maintains Overweight
04/28/2022 149.67% Credit Suisse → $19 Initiates Coverage On → Neutral
02/10/2022 149.67% Wells Fargo → $19 Initiates Coverage On → Equal-Weight
10/14/2021 162.81% SVB Leerink → $20 Initiates Coverage On → Market Perform
07/19/2021 294.22% Guggenheim → $30 Initiates Coverage On → Buy
07/19/2021 425.62% Piper Sandler → $40 Initiates Coverage On → Overweight
07/19/2021 399.34% JP Morgan → $38 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/03/2023 149.67% 富國銀行 →$19 升級 等重→超重
10/13/2022 189.09% 瑞銀集團 →$22 開始承保 →購買
2022年08月15日 162.81% 傑富瑞 →$20 開始承保 →購買
2022年05月12日 175.95% 派珀·桑德勒 $40→$21 維護 超重
04/28/2022 149.67% 瑞士信貸 →$19 開始承保 →中性
02/10/2022 149.67% 富國銀行 →$19 開始承保 →等重
10/14/2021 162.81% SVB Leerink →$20 開始承保 →市場表現
07/19/2021 294.22% 古根海姆 →$30 開始承保 →購買
07/19/2021 425.62% 派珀·桑德勒 →$40 開始承保 →超重
07/19/2021 399.34% 摩根大通 →$38 開始承保 →超重

What is the target price for Monte Rosa Therapeutics (GLUE)?

蒙特羅薩治療公司(GLUE)的目標價格是多少？

The latest price target for Monte Rosa Therapeutics (NASDAQ: GLUE) was reported by Wells Fargo on January 3, 2023. The analyst firm set a price target for $19.00 expecting GLUE to rise to within 12 months (a possible 149.67% upside). 6 analyst firms have reported ratings in the last year.

富國銀行於2023年1月3日報道了蒙特羅薩治療公司(納斯達克：GLUE)的最新目標價。這家分析公司將目標價定為19美元，預計12個月內膠價將上漲至149.67%。6家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?

蒙特羅薩治療公司(GLUE)的最新分析師評級是多少？

The latest analyst rating for Monte Rosa Therapeutics (NASDAQ: GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics upgraded their overweight rating.

蒙特羅薩治療公司(納斯達克代碼：GLUE)的最新分析師評級由富國銀行提供，蒙特羅薩治療公司上調了其增持評級。

When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?

蒙特羅薩治療公司(GLUE)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on January 3, 2023 so you should expect the next rating to be made available sometime around January 3, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與蒙特羅薩治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。蒙特羅薩治療公司的上一次評級是在2023年1月3日提交的，所以你應該預計下一次評級將在2024年1月3日左右的某個時候提供。

Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?

分析師對蒙特羅薩治療公司(GLUE)的評級正確嗎？

While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a upgraded with a price target of $0.00 to $19.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $7.61, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的蒙特羅薩治療公司(GLUE)評級被上調，目標價為0.00美元至19.00美元。蒙特羅薩治療公司(GLUE)目前的交易價格為7.61美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論